Get started
Author

Antonio Pellino

Observed names: A. Pellino, PELLINO, ANTONIO, Pellino, Antonio
Observed institutions: University of Pisa, University of Padua, Istituto Oncologico Veneto, Ospedale di Livorno, Azienda Ospedaliera Universitaria Pisana, Azienda USL Toscana Nord Ovest
ORCID: 0000-0003-4166-5044
Observed ORCID: 0000-0003-4166-5044
OpenAlex ID: A5086193660
Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas
2021 · Antonio Pellino, Stefano Brignola, et al. · Journal of Personalized Medicine · 163
PDF
Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases
2019 · Irene Coati, Gábor Lotz, et al. · British Journal of Cancer · 135
PDF
Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives
2019 · Antonio Pellino, Erika Riello, et al. · World Journal of Gastroenterology · 93
Precision medicine in cholangiocarcinoma
2018 · Antonio Pellino, Fotios Loupakis, et al. · Translational Gastroenterology and Hepatology · 79
PDF
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors
2024 · Brigida Anna Maiorano, Massimo Di Maio, et al. · JAMA Network Open · 55
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
2021 · Valentina Burgio, Massimo Iavarone, et al. · Cancer Management and Research · 44
PDF
PD-L1 expression in gastroesophageal dysplastic lesions
2019 · Matteo Fassan, Stefano Brignola, et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 31
Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study
2022 · Mario Rizzato, Stefano Brignola, et al. · European Journal of Cancer · 30
Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study
2023 · Floriana Nappo, Lorenzo Fornaro, et al. · Journal of Cancer Research and Clinical Oncology · 29
Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis
2020 · Daniele Rossini, Marco Maria Germani, et al. · Clinical Colorectal Cancer · 26
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma
2021 · I.G. Rapposelli, S. Shimose, et al. · ESMO Open · 20
PDF
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis
2021 · Andrea Casadei-Gardini, Lorenza Rimassa, et al. · Journal of Cancer Research and Clinical Oncology · 20
Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action
2023 · Lorenzo Fornaro, Sara Lonardi, et al. · Gastric Cancer · 12
PDF
Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and Clinical Outcomes in MSI-H population: The PROSECCO Study.
2022 · Floriana Nappo, Antonio Pellino, et al. · Journal of Clinical Oncology · 6
Observational retrospective evaluation of treatment with liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic cancer patients: An Italian large real-world analysis.
2020 · Antonio Pellino, Chiara Manai, et al. · Journal of Clinical Oncology · 4
Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort
2019 · Andrea Casadei-Gardini, Leonardo Solaini, et al. · Gastrointestinal Tumors · 4
PDF
Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study
2023 · Luigi Coltelli, Chiara Finale, et al. · Clinical and Experimental Medicine · 2
PDF
Current Landscape and Evolving Role of Targeted Agents in Urothelial Carcinoma
2026 · Enrico Sammarco, Antonio Pellino, et al. · Cancers · 1
PDF
Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall Survival
2026 · Luigi Coltelli, Paola Orlandi, et al. · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 1
PDF
Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis
2019 · D. Rossini, F. Pagani, et al. · Annals of Oncology · 1
PDF
Adjuvant chemotherapy with cisplatin and gemcitabine compared with standard of care after curative intent resection of cholangiocarcinoma and muscle-invasive gallbladder carcinoma (ACTICCA-1/AIO-HEP-0112 trial)
2026 · A. Stein, J. Bridgewater, et al. · Annals of Oncology
PDF
NRG1 fusions in non-small cell lung cancer: biology, diagnostics, and emerging HER2/HER3 therapies—a narrative review
2026 · Andrea Marini, Irene Stasi, et al. · Translational Lung Cancer Research
Mixed endometrial carcinoma: is it time to profile the two components separately?
2026 · Gianna Musettini, Paola Pretelli, et al. · Frontiers in Oncology
PDF
Efficacy of retreatment with anti-EGFRs in mCRC is not predictable by clinical factors related to prior lines of therapy: A multi-institutional analysis.
2019 · Daniele Rossini, Filippo Pagani, et al. · Journal of Clinical Oncology
FOLFOXIRI plus bevacizumab (bev) as upfront treatment for metastatic colorectal cancer (mCRC) patients (pts) with initially unresectable liver-limited disease (LLD)
2016 · M. Casagrande, C. Cremolini, et al. · Annals of Oncology
Works count: 27
Citation count: 756
H-index: 12
I10-index: 13
Year
Topic
Type